ACHL - Achilles Therapeutics GAAP EPS of -$0.32 beats by $0.33 November, 08 2022 09:22 AM Achilles Therapeutics plc Achilles Therapeutics press release ( NASDAQ: ACHL ): Q3 GAAP EPS of -$0.32 beats by $0.33 . Cash and cash equivalents were $179.9 million as of September 30, 2022, as compared to $266.3 million as of December 31, 2021. For further details see: Achilles Therapeutics GAAP EPS of -$0.32 beats by $0.33